Loading
A phase 1 trial of DBC-664 run by Duboce Biopharmaceuticals, Inc., now recruiting.
DBC-664 in Adult Patients With Solid Tumors is a phase 1 interventional study registered as NCT07705035 by Duboce Biopharmaceuticals, Inc., with 210 participants planned, started 2026-07-17. Conditions recorded: Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma, Endometrial Adenocarcinoma and Ovarian Adenocarcinoma. Interventions recorded: DBC-664.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Ovarian cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Ovarian cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Ovarian cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/